Pexidartinib
Pexidartinib is a selective CSF1R inhibitor that depletes tumour-associated macrophages (TAMs) by blocking M-CSF signalling critical for monocyte-macrophage survival and differentiation. TAM depletion reduces immunosuppression and enhances T-cell infiltration. FDA-approved for adults with symptomatic tenosynovial giant cell tumour (TGCT/PVNS); serious hepatotoxicity risk requires REMS enrollment.
Description
Scientific Overview: Pexidartinib is a selective CSF1R inhibitor that depletes tumour-associated macrophages (TAMs) by blocking M-CSF signalling critical for monocyte-macrophage survival and differentiation. TAM depletion reduces immunosuppression and enhances T-cell infiltration. FDA-approved for adults with symptomatic tenosynovial giant cell tumour (TGCT/PVNS); serious hepatotoxicity risk requires REMS enrollment.
Mechanism of Action: CSF1R / KIT / FLT3 Inhibitor
Purity: ≥99% | Molecular Formula: C20H15ClF3N5
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | CSF1R / KIT / FLT3 Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C20H15ClF3N5 |
| CAS Number | 1029044-16-3 |
